Cytodyn Inc (CYDY)

[misiu143]

In your post..

" Individual monoclonal antibody products be developed with expectation that they will be combined with one or more monoclonal antibody products that bind to DIFFERENT EPITOPES to minimize the risk of long acting against emerging variants.."


Rockleo understood very well I believe , they developing more neutralizing monoclonal antibodies , binding in different place of the virus then present , to cover more mutation..

And recently in a different paper with Dr Woodcocck , she name it , neutralizing monoclonal antibodies , we will be spending more money to develop ..

So really nothing with us IMO..